Homeostasis in early postoperative period in patients after nephrectomy with thrombectomy of inferior vena cava performed for locally advanced kidney cancer
- Authors: Prikhodchenko A.O.1, Feoktistov P.I.2, Shin A.R.2, Vyatkin P.V.3, Baydal O.V.1,3
-
Affiliations:
- Scientific and Educational Center “Eurasian Cancer Program “EAFO”
- National Medical Research Center of Oncology named after N.N. Blokhin
- V.A. Nasonova Research Institute of Rheumatology
- Issue: Vol 6, No 2 (2025)
- Pages: 55-65
- Section: Original Study Articles
- URL: https://journals.rcsi.science/2658-4433/article/view/357337
- DOI: https://doi.org/10.17816/clinutr693264
- EDN: https://elibrary.ru/KKTJAV
- ID: 357337
Cite item
Full Text
Abstract
BACKGROUND: Nephrectomy with thrombectomy of the inferior vena cava is an effective treatment for kidney cancer complicated by tumor thrombus (TT). However, this surgical intervention carries a high risk of severe homeostatic disturbances in the early postoperative period.
AIM: This study aimed to evaluate the changes in metabolic parameters in the early postoperative period in patients undergoing nephrectomy with inferior vena cava thrombectomy without extracorporeal circulation.
METHODS: This observational study included 682 patients who underwent nephrectomy with thrombectomy for kidney cancer with TT. According to the Mayo Clinic classification, patients were divided into three groups based on the proximal extent of TT: Infrahepatic (InH, levels I and II), Retrohepatic (RH, level III), and Supradiaphragmatic (SD, level IV). Complete blood count, blood biochemistry, and coagulation profile were assessed at three time points: stage 1 (S1), preoperatively; stage 2 (S2), morning of postoperative day 1; and stage 3 (S3), morning of postoperative day 2.
RESULTS: Analysis of hematology, coagulation, and biochemistry parameters revealed significant postoperative changes. A progressive decrease in platelet concentration was observed from stage to stage, with intergroup differences most pronounced in the InH group. Erythrocyte concentration significantly decreased at S3 in the RH group. Fibrinogen concentration demonstrated a complex pattern. The highest values were recorded in the InH group at S1. Significant differences between all groups persisted at subsequent stages, whereas key coagulation parameters remained stable.
The biochemistry profile was characterized by a significant increase in urea and creatinine concentrations by S3 in all groups. Total bilirubin, total protein, and albumin concentrations significantly decreased after S1. Alanine aminotransferase and aspartate aminotransferase activities differed significantly between stages but not between groups. Pancreatic amylase concentration did not change. Despite statistically significant fluctuations, plasma lactate concentration remained within reference ranges in all cases.
CONCLUSION: The frequency and severity of homeostatic disturbances after nephrectomy with thrombectomy of inferior vena cava directly correlate with the extent of the TT.
Full Text
##article.viewOnOriginalSite##About the authors
Aleksey O. Prikhodchenko
Scientific and Educational Center “Eurasian Cancer Program “EAFO”
Author for correspondence.
Email: Evpatii2004@mail.ru
ORCID iD: 0000-0002-4770-0034
SPIN-code: 1318-3744
MD, Cand. Sci. (Medicine)
Russian Federation, MoscowPavel I. Feoktistov
National Medical Research Center of Oncology named after N.N. Blokhin
Email: festeraddamzz@mail.ru
ORCID iD: 0000-0001-6024-5817
SPIN-code: 3146-5044
MD, Cand. Sci. (Medicine)
Russian Federation, MoscowAlexandr R. Shin
National Medical Research Center of Oncology named after N.N. Blokhin
Email: dr.alex.shin@gmail.com
ORCID iD: 0000-0002-3595-3472
SPIN-code: 6255-5915
MD, Cand. Sci. (Medicine)
Russian Federation, MoscowPavel V. Vyatkin
V.A. Nasonova Research Institute of Rheumatology
Email: pablo2002@yandex.ru
ORCID iD: 0000-0003-2976-2562
SPIN-code: 8796-4806
Russian Federation, Moscow
Oleg V. Baydal
Scientific and Educational Center “Eurasian Cancer Program “EAFO”; V.A. Nasonova Research Institute of Rheumatology
Email: o.baydal@yandex.ru
ORCID iD: 0009-0002-7623-6733
Russian Federation, Moscow; Moscow
References
- Abel EJ, Thompson RH, Margulis V, et al. Perioperative outcomes following surgical resection of renal cell carcinoma with inferior vena cava thrombus extending above the hepatic veins: a contemporary multicenter experience. Eur Urol. 2014;66(3):584–592. doi: 10.1016/j.eururo.2013.10.029
- Davydov MI, Matveev VB. Surgical treatment of kidney cancer with tumor thrombosis of the renal vein and inferior vena cava. Clinical cancer urology. Moscow: Verdana; 2001. P:143–179. (In Russ.)
- Matveev VB, Volkova MI, Vashakmadze NL, Stilidi IS. Technique and short-term outcomes of surgical treatment in patients with renal cell carcinoma and tumor venous thrombosis: experience of the Urology Clinic, N.N. Blokhin National Medical Research Center of Oncology. Cancer Urology. 2021;17(2):17–32. doi: 10.17650/1726-9776-2021-17-2-17-32 EDN: ZDLFGZ
- Davydov MI, Matveev VB, Volkova MI, et al. Surgical treatment of renal cell carcinoma with level III–IV tumor thrombus. Cancer Urology. 2016;12(4):21–34. doi: 10.17650/1726-9776-2016-12-4-21-34 EDN: ZEORLD
- Pouliot F, Shuch B, Larochelle JC, et al. Contemporary management of renal tumors with venous tumor thrombus. J Urol. 2010;184(3):833–841. doi: 10.1016/j.juro.2010.04.071 EDN: OLKAFJ
- Simon RM, Kim T, Espiritu P, et al. Effect of utilization of veno-venous bypass vs. cardiopulmonary bypass on complications for high level inferior vena cava tumor thrombectomy and concomitant radical nephrectomy. Int Braz J Urol. 2015;41(5):911–919. doi: 10.1590/S1677-5538.IBJU.2014.0371
- Nguyen HG, Tilki D, Dall’Era MA, et al. Cardiopulmonary bypass has no significant impact on survival in patients undergoing nephrectomy and level III-IV inferior vena cava thrombectomy: multi-institutional analysis. J Urol. 2015;194(2):304–309. doi: 10.1016/j.juro.2015.02.2948
- Gorobets YeS, Feoktistov PI. The specific features of an-esthesiological provision of operations removing malignant neoplasms with a tumorous thrombus in the inferior cava vein. Anesteziologiia i reanimatologiia. 2005;(5):9–13. EDN: HTPKZX
- Toren R, Abouassaly N, Timilshina G, et al. Results of a national populationbased study of outcomes of surgery for renal tumors associated with inferior vena cava thrombus. Urology. 2013;82(3):572–577. doi: 10.1016/j.urology.2013.04.054
- Martínez-Salamanca JI, Linares E, González J, et al. Lessons learned from the international renal cell carcinoma–venous thrombus consortium (IRCC–VTC). Curr Urol Rep. 2014;15(5):1–9. doi: 10.1007/s11934-014-0404-7 EDN: IYHDTT
- Parra J, Drouin SJ, Hupertan V, et al. Oncological outcomes in patients undergoing radical nephrectomy and vena cava thrombectomy for renal cell carcinoma with venous extension: a single-centre experience. EJSO. 2011;37(5):422–428. doi: 10.1016/j.ejso.2011.01.028 EDN: OMOMQV
- Feoktistov PI, Shin AR, Prikhodchenko AO, et al. Massive blood loss in surgery for renal cell carcinoma associated with inferior vena cava tumor thrombus: Observational study. Consilium Medicum. 2022;24(6):429–434. doi: 10.26442/20751753.2022.6.201705 EDN: HQFTZN
- Nekhaev IV, Prikhodchenko AO, Mazurina OG, et al. Multiple organ failure, SIRS, thrombohemorrhagic syndrome and antithrombin III. Infektsii v khirurgii. 2015;13(1):17–26. EDN: UINNWN
- Nekhaev IV, Prikhodchenko AO, Mazurina OG, et al. Antithrombin III in intensive care. Tromboz, gemostaz i reologiya. 2015;1(61):13–21. EDN: TNGBJV
- Nekhaev IV, Prikhodchenko AO, Zhuzhginova OV, et al. Recombinant factor VIIa in intensive care. Gematologiya i transfuziologiya. 2015;60(2):32–39. EDN: TXKIRH
- Nekhaev IV, Prikhodchenko AO, Lomidze SV, Sytov AV. Eptacog Alfa. Clinical Experience. Tromboz, gemostaz i reologiya. 2017;4(72):63–69. doi: 10.25555/THR.2017.4.0812 EDN: ZQTYFZ
- Nekhaev IV, Prikhodchenko AO, Vyatkin PV, et al. Perioperative coagulopathies in oncosurgery. Prothrombin complex concentrate. Tromboz, gemostaz i reologiya. 2016;1(65):39–50. EDN: VMNMHT
- Feoktistov PI, Shin AR, Prikhodchenko AO, et al. Infusion-transfusion therapy in treatment of acute massive surgical blood loss in cancer surgery. Tromboz, gemostaz i reologiya. 2021;(4):38–48. doi: 10.25555/THR.2021.4.0995 EDN: AEJOYU
Supplementary files


